Skip to main content
SpringerLink
Log in

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.

Patients and methods. This was a phase II study with 91 patients randomized between either doxorubicin (60 mg/m2) followed immediately by paclitaxel (200 mg/m2 over 3 h) (AT), or with doxorubicin (60 mg/m2) followed immediately by cyclophosphamide (600 mg/m2) (AC). Treatment was limited to six cycles of therapy for the doxorubicin and paclitaxel combination. Left ventricular ejection fraction was evaluated at on study and after four and six cycles of treatment on AT.

Results. Estimates of overall objective response were 31% (with 9% CR) and 39% (with 11% CR) for patients on the AT and AC regimens, respectively. Response was lower than anticipated on the standard AC arm. On average the reduction of LVEF was similar in the two groups, with no patients developing congestive heart failure during the six cycles of therapy, although one patient in the AT group died of delayed congestive heart failure.

Conclusions. The results of this multi-institutional study in patients with metastatic breast cancer suggest that the combination of doxorubicin and paclitaxel is well tolerated with relatively low rates of cardiac toxicity if the total dose of doxorubicin is held to ≤360 mg/m2. However, the CR rates achieved with this combination are probably more modest than initial single institution studies might suggest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hortobagyi GN: Treatment of breast cancer. New England J Med 339: 974–984, 1998

    Google Scholar 

  2. Gianni L: Paclitaxel plus doxorubicin in metastatic breast cancer: the Milan expierence. Oncology 12(1 Suppl 1): 13–15, 1998

    Google Scholar 

  3. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spearfish C, Laffranchi A, Caraceni A, Martini C et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995

    Google Scholar 

  4. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687–693, 1996

    Google Scholar 

  5. Green S, Weiss G: Southwest Oncology Group standard response criteria endpoint definitions and toxicity criteria. Invest New Drugs 10: 239–253, 1992

    Google Scholar 

  6. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC: Phase III trail of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Study Group (E4195). Breast Cancer Res Treat 46: 23,3a, 1997

    Google Scholar 

  7. Slamon D, Lyeland-Jones B, Shak S, Paton V, Bajomonde A, Fleming T, Elermann W, Wolter J, Baselga J, Norton L: Addition of herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc ASCO 17: 377a, 1998

    Google Scholar 

  8. Panday VR, ten Bokkel Huinink WW, Rosing H, Koopman FJ, Hillebrand MJ, Dubbelman RC, van Tellingen O, Schellens JH, Beijnen JH: Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. Anti-Cancer Drugs 9: 665–673, 1998

    Google Scholar 

  9. Sparano JA: Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies. Semin Oncol 25(6 Suppl 13): 10–15, 1998

    Google Scholar 

  10. Dieras V: Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Semin Oncol 25(5 Suppl 12): 18–22, 1998

    Google Scholar 

  11. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU: Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24(5 Suppl 17): S17-65–S17-68, 1997

    Google Scholar 

  12. Amadori D, Frassineti GL, Zolti W. et al.: A phase I/II study of paclitaxel and doxorubicin in treatment of advanced breast cancer. Semin Oncol 23: 19–23, 1996

    Google Scholar 

  13. Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L: Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 16: 67–71, 1998

    Google Scholar 

  14. Sledge GW, Neuberg D, Ingle J et al.: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin +paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MCB): an intergroup trial. Proc Am Soc Clin Oncol 16: 1a, 1997

    Google Scholar 

  15. Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, Balis F, Venzon D, McCabe M, Goldspiel B, Chow C, Ognibene FP, O'Shaughnessy J: Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14: 774–782, 1996

    Google Scholar 

  16. deMagalhaes-Silverman M, Hammert L, Lembersky B, Lister J, Rybka W, Ball E: High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy. Bone Marrow Transplant 21: 1207–1211, 1998

    Google Scholar 

  17. Moliterni A, Tarenzi E, Capri G et al.: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol 24: S17-10–S17-14

  18. Martin M, Lluch A, Ojeda B et al.: Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Semin Oncol 24(5): S17-26–S17-30, 1997

    Google Scholar 

  19. Klein JL, Dansey RD, Karanes C et al.: Induction chemotherapy with doxorubicin and paclitaxel for metastatic breast cancer. 20th Annual San Antonio Breast Cancer Symp: Breast Cancer Res Treat 46: 94, October 1997

    Google Scholar 

  20. Papadimitriou CA, Dimopoulos MA, Ampela C, Louvrou-Fertaki A, Anagnostopoulos A, Athanassiades P, Stamatelopoulos S, Keramopoulos A: Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer. Oncology 55: 533–537, 1998

    Google Scholar 

  21. Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF: A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology 11(4 Suppl 3): 024–29, 1997

    Google Scholar 

  22. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lahrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20: 3114–3121, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, 601 Elmwood Avenue, Box 704, Rochester, NY, 14642-0001, USA

    Gary H. Lyman

  2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

    Stephanie J. Green

  3. University of Texas Health Science Center, San Antonio, TX, USA

    Peter M. Ravdin & Charles E. Geyer Jr.

  4. University of Southern California, Los Angeles, CA, USA

    Christy A. Russell

  5. Ohio State University, Columbus, USA

    Stanley P. Balcerzak

  6. Cleveland Clinic, Cleveland, OH, USA

    G. Thomas Budd

  7. John Wayne Cancer Institute, Santa Monica, CA, USA

    Silvana Martino

Authors
  1. Gary H. Lyman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie J. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter M. Ravdin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles E. Geyer Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christy A. Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Thomas Budd
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Silvana Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary H. Lyman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyman, G.H., Green, S.J., Ravdin, P.M. et al. A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer. Breast Cancer Res Treat 85, 143–150 (2004). https://doi.org/10.1023/B:BREA.0000025405.63953.f9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000025405.63953.f9

Search

Navigation